Papulopustular Eruptions Associated With EGFR-Pathway-Related Targeted Therapies: Clinical Spectrum, Evidence Boundaries, Folliculocentric Inflammation, and Management Considerations
July 2026
in “
Frontiers in Oncology
”
Studysummary This mini review reports on papulopustular eruptions linked to classical EGFR inhibitors, MEK inhibitors, and amivantamab, highlighting distinct dermatologic toxicities in each treatment context and exploring underlying mechanisms and management strategies.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on frontiersin.org →